ddI & ddC

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: ddI & ddC
• 英文别名: 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
• 化学式: C19H25N7O6
• 分子量: 447.4
• InChiKey: OVTYPGOGMBRBHP-TVGXNDPCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.72
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  177
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
  申请人：The Board of Trustees of the University of Illinois

  公开号：US10058585B2

  公开（公告）日：2018-08-28

  The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals. The invention specifically includes mutants with altered Eph binding constants and selectivities.

  本发明涉及干扰哺乳动物细胞中ephrin信号系统的铜绿素以及铜绿素的变体、衍生物和结构等价物的组合物和使用方法。具体而言，本发明涉及使用铜红菌素（如azurin、rusticyanin和plastocyanin）及其变体、衍生物和结构等效物治疗哺乳动物癌症的组合物和方法。本发明特别包括具有改变的 Eph 结合常数和选择性的突变体。
• HIV PROTEASE INHIBITORS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1112269A2

  公开（公告）日：2001-07-04
• FLT3L-FC FUSION PROTEINS AND METHODS OF USE
  申请人：GILEAD SCIENCES, INC.

  公开号：EP3990476A1

  公开（公告）日：2022-05-04
• COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS AND MUTANTS THEREOF
  申请人：The Board of Trustees of the University of Illinois

  公开号：US20160151452A1

  公开（公告）日：2016-06-02

  The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals. The invention specifically includes mutants with altered Eph binding constants and selectivities.
• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEASE DU VIH
  申请人：WARNER LAMBERT CO

  公开号：WO2000015634A2

  公开（公告）日：2000-03-23

  The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.